Kiran Mazumdar-Shaw Weighs $4.5 Billion Biocon Biologics Move: IPO or Merger on the Table

Biocon Biologics Faces Crucial Crossroads: IPO or Merger Strategy

Biocon Group chairperson Kiran Mazumdar-Shaw has confirmed that the company is exploring multiple options to unlock value from its biosimilars arm, Biocon Biologics Ltd, valued around $4.5 billion. The options include an IPO, a merger with the parent company Biocon Ltd, or a share swap mechanism involving minority shareholders.

Earlier plans for an IPO faced headwinds due to acquisition debt from Biocon Biologics' $3.3 billion purchase of Viatris’ biosimilars business and current market uncertainties. Mazumdar-Shaw revealed that Morgan Stanley has been appointed to conduct a detailed evaluation to identify the best route for value creation.

She emphasized that a merger could provide a quicker value unlock compared to an IPO, which depends heavily on market conditions. Discussions include cash-plus-swap structures and share swaps with minority investors, aiming to reduce acquisition-related debt and enhance Biocon’s balance sheet strength.

Biocon raised ₹4,500 crore via a qualified institutional placement earlier in 2025 to increase its stake in Biocon Biologics and to provide exit options to some private equity investors.

This move signals Biocon’s strategic flexibility in choosing the ideal path for growth and shareholder returns amid a complex global biosimilars environment.

Key Highlights:

Biocon Biologics valued at approx. $4.5 billion; IPO and merger considered.

Acquisition debt (~$1.2 billion) from Viatris deal influences strategy.

Morgan Stanley appointed to recommend best value unlocking option.

Mix of IPO, merger, share swap, and cash-plus-swap structures under review.

Biocon raised ₹4,500 crore in QIP to consolidate stake and reduce debt.

Strategy aims to strengthen balance sheet and maximize shareholder value.

Source: Hindustan Times, Moneycontrol, Economic Times, Business Standard (2025)